Search
Citações e referências (7)
Gibco™
CTS™ OpTmizer™ T Cell Expansion SFM, bottle format
GIBCO OpTmizer™ CTS™ T-Cell Expansion SFM has been developed for the growth and expansion of human T lymphocytes. OpTmizer™ CTS™Leia mais
| Número do catálogo | Quantity |
|---|---|
| A1048501 | 1000 mL |
Número do catálogo A1048501
Preço (BRL)
1.669,72
Each
Quantity:
1000 mL
Preço (BRL)
1.669,72
Each
GIBCO OpTmizer™ CTS™ T-Cell Expansion SFM has been developed for the growth and expansion of human T lymphocytes. OpTmizer™ CTS™ T-Cell Expansion medium is a complete serum-free, xeno-free 1X medium consisting of OpTmizer™ T-Cell Expansion Basal Medium (1 L bottle) and OpTmizer™ T-Cell Expansion Supplement (26 mL), which are mixed together prior to use.
• Maintains similar phenotype and function (e.g., cytokine secretion profile) of polyclonally activated and cultured T cells as observed for conventional serum supplemented medium
• Consistent performance in supporting T cell expansion
• Supports high density T cell culture (e.g., >3x106 CD3+ T cells/mL) in static culture
With OpTmizer™ T-Cell Expansion SFM, we offer both basic and clinical research communities a new tool to enhance their success in growing human T-cells. It is specially formulated to allow for superior cell growth & viability, less variability and more consistent results, and easier transition from research to clinical applications.
Workflow benefits:
• Minimizing the need to handle purchasing, storage, qualification of serum and thus reducing variability and costs
• More rapid T cell expansion, thus reducing cycle time and improving productivity
• Complete serum-free, xeno-free medium, allowing for a seamless transition from research to clinical applications and minimizing regulatory workload
• Maintains similar phenotype and function (e.g., cytokine secretion profile) of polyclonally activated and cultured T cells as observed for conventional serum supplemented medium
• Consistent performance in supporting T cell expansion
• Supports high density T cell culture (e.g., >3x106 CD3+ T cells/mL) in static culture
With OpTmizer™ T-Cell Expansion SFM, we offer both basic and clinical research communities a new tool to enhance their success in growing human T-cells. It is specially formulated to allow for superior cell growth & viability, less variability and more consistent results, and easier transition from research to clinical applications.
Workflow benefits:
• Minimizing the need to handle purchasing, storage, qualification of serum and thus reducing variability and costs
• More rapid T cell expansion, thus reducing cycle time and improving productivity
• Complete serum-free, xeno-free medium, allowing for a seamless transition from research to clinical applications and minimizing regulatory workload
Especificações
Cell TypeT Cells
Culture EnvironmentCO2
Endotoxin LevelVery Low
Included AntibioticsNo antibiotics
Inorganic SaltsCalcium, Magnesium
Product LineCTS, OpTmizer
Product TypeCell Expansion Serum Free Medium (SFM)
Purity or Quality GradeResearch Grade
Quantity1000 mL
ClassificationSerum-free, Xeno-free
Culture TypeSuspension Cell Culture
FormLiquid
Serum LevelSerum-free
SterilitySterile
With AdditivesHEPES, Phenol Red, Sodium Pyruvate, Sodium Bicarbonate
Without AdditivesNo Glutamine
Unit SizeEach
Conteúdo e armazenamento
OpTmizer™ T-Cell Expansion Basal Medium (1 x 1000 mL bottle): Store at 2–8°C. Protect from light.
OpTmizer™ T-Cell Expansion Supplement (1 x 26 mL): Store in the dark at 2–8°C.
OpTmizer™ T-Cell Expansion Supplement (1 x 26 mL): Store in the dark at 2–8°C.
Frequently asked questions (FAQs)
What is CTS?
Do I need to order additional components with the CTS OpTmizer T Cell Expansion SFM (Cat. Nos. A1048501, A1048502, A1048503)?
Will CTS OpTmizer T Cell Expansion SFM (Cat. No. A1048501, A1048502, A1048503) work with all types of T cells?
Can CTS OpTmizer T Cell Expansion SFM (Cat. Nos. A1048501, A1048502, A1048503) be used for animal T cell cultures other than human?
Is there a difference in formulation of the CTS OpTmizer T Cell Expansion SFM between the bottle and bag packaging formats?
Citações e referências (7)
Citações e referências
Abstract
Performance of serum-supplemented and serum-free media in IFNgamma Elispot Assays for human T cells.
Journal:Cancer Immunol Immunother
PubMed ID:19894047
'The choice of serum for supplementation of media for T cell assays and in particular, Elispot has been a major challenge for assay performance, standardization, optimization, and reproducibility. The Assay Working Group of the Cancer Vaccine Consortium (CVC-CRI) has recently identified the choice of serum to be the leading cause
Impact of culture medium on the expansion of T cells for immunotherapy.
Journal:Cytotherapy
PubMed ID:19903105
'BACKGROUND AIMS: Encouraging evidence of clinical benefits from cancer immunotherapy is beginning to accumulate in several clinical trials. Cancer immunotherapy is based on two main methods, active vaccination and cell-transfer therapy. The ex vivo expansion of T cells is required to monitor vaccine-induced antigen-specific T cells or prepare large numbers
Ex vivo expansion of human T cells for adoptive immunotherapy using the novel Xeno-free CTS Immune Cell Serum Replacement.
Journal:
PubMed ID:25671129
The manufacture of clinical grade cellular products for adoptive immunotherapy requires ex vivo culture and expansion of human T cells. One of the key components in manufacturing of T cell therapies is human serum (HS) or fetal bovine serum (FBS), which can potentially expose immunotherapy recipient to adventitious infectious pathogens
Bioengineering and serum free expansion of blood-derived ?d T cells.
Journal:Cytotherapy
PubMed ID:27260209
'Cellular immunotherapy relies on several highly variable patient-specific parameters, such as (i) cell number before and after expansion, (ii) targeting of cells to tumors, (iii) cell survival and function after infusion, and (iv) on- and off-target adverse events. Cellular approaches such as the specific expansion of ?d T cells as
A Rapid Cell Expansion Process for Production of Engineered Autologous CAR-T Cell Therapies.
Journal:Hum Gene Ther Methods
PubMed ID:27897048
The treatment of B-cell malignancies by adoptive cell transfer (ACT) of anti-CD19 chimeric antigen receptor T cells (CD19 CAR-T) has proven to be a highly successful therapeutic modality in several clinical trials.(1-6) The anti-CD19 CAR-T cell production method used to support initial trials relied on numerous manual, open process steps,